Eli Lilly (LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly plans four new U.S. manufacturing sites, expanding domestic production and reshoring pharmaceutical ingredient manufacturing. $50B expansion since 2020 includes four sites, creating over ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.

New York (AFP) – US pharmaceutical giant Eli Lilly announced Wednesday that it will build four additional new manufacturing sites in the United States in a committment designed to influence ...